Indegene Q1: revenue up 40% YoY but consolidated PAT flat at ₹116 Cr on margin squeeze

Indegene's Q1 FY27 (consolidated) print is a classic growth-vs-margin split: revenue from operations rose ~40% YoY to ₹1,063 Cr — its second straight quarter above the ₹1,000 Cr mark — yet net profit was essentially flat at ₹116.2 Cr versus ₹116.4 Cr a year ago. EPS held at ₹4.84 (vs ₹4.86). The 45% QoQ jump in PAT looks flattering but is an artefact of the prior quarter's ₹20.3 Cr TCPA litigation exceptional; stripped of that, there was no exceptional in either the current or the year-ago period, so underlying YoY PAT growth is ~0%. The story of the quarter is therefore the bottom line, not the top line.

The squeeze sits below the revenue line. EBITDA margin fell to ~16.4% from ~20.4% a year ago (NPM 10.9% vs 14.9%), as costs outran the topline: other expenses surged ~85% YoY to ₹229.8 Cr and employee benefits rose ~37% to ₹659 Cr — the fingerprint of the newly consolidated acquired agencies (the Cake Kommunikations group, BioPharm, Trilogy, MJL units now sit in the subsidiary list). That acquisition drag is confined to the group: standalone PAT actually grew ~33% YoY to ₹59.9 Cr on 33% higher revenue, a materially better trajectory than the flat consolidated line — readers comparing the two numbers should note the gap is the loss/margin dilution from freshly folded-in overseas units, not an error.

The stock went into the print at ₹514.7, down 0.1% over the past month of trading.

For context: revenue is at a 6-quarter high.

Against management's own framing from the Q4 concall — no formal revenue guidance, but EBITDA-margin improvement 'throughout FY27' with a return to prior (~20%) levels only in H2, plus a 'significant upward movement in PAT' — this is an on-plan but not-yet-delivering start: margins are roughly flat sequentially (ex the Q4 one-off) and the promised PAT uplift has yet to appear. Segment mix shows Enterprise Commercial Solutions leading at ₹750 Cr (+44% YoY) versus Enterprise Medical Solutions ₹274 Cr (+28%). Alongside the result the board approved an ESOP allotment and the company goes ex a ₹2.25/share final FY26 dividend (record date July 31, ~₹54 Cr outflow). The setup into Q2–H2 is straightforward to judge: revenue momentum is intact, but the entire investment case now rests on the acquired units becoming margin-accretive and management hitting its H2 margin-recovery marker.